Cover Image
市場調查報告書

美國的經皮吸收貼片市場與臨床實驗分析

US Transdermal Patch Market & Clinical Trial Insight

出版商 KuicK Research 商品編碼 344406
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的經皮吸收貼片市場與臨床實驗分析 US Transdermal Patch Market & Clinical Trial Insight
出版日期: 2015年11月03日 內容資訊: 英文 300 Pages
簡介

美國和全球其他市場比較,其經皮貼片消費者群也極度高。女性用避孕藥、尼古丁替代療法 (NRT) 等在近數年更是得到各方注目。胰島素貼片、疫苗3前雖仍處於實驗階段,但今後數年中可望產品化。

本報告提供美國的經皮吸收貼片市場相關調查分析,提供您市場概要,價值鏈分析,醫藥品受託製造廠商 (CMO) 、臨床實驗平台分析,臨床實驗平台,前臨床階段的主要產品,已上市產品等系統性資訊。

第1章 經皮吸收貼片概要

第2章 經皮吸收貼片的種類

  • 單層/多層式的藥物黏劑
  • 藥池型的經皮吸收貼片
  • Matrix型的經皮吸收貼片
  • 蒸氣貼片
  • 主動/被動貼片

第3章 經皮吸收貼片的藥物遞輸的機制

第4章 經皮吸收貼片的優點

第5章 美國的經皮吸收貼片市場概要

  • 目前市場方案
  • 經皮吸收貼片的臨床實驗平台概要

第6章 非專利/品牌的經皮吸收貼片

第7章 美國的經皮吸收貼片市場:價值鏈分析

  • 研究開發
  • 製造
  • 行銷·流通
  • 終端用戶價格

第8章 美國的經皮吸收貼片CMO

第9章 美國的經皮吸收貼片推動市場成長要素

  • 帕金森氏症
  • 老年癡呆症
  • 女性用避孕藥
  • 尼古丁替代療法 (NRT)
  • 胰島素
  • 疫苗

第10章 美國的經皮吸收貼片市場形勢

  • 可喜的市場參數
  • 商業化的課題

第11章 美國的經皮吸收貼片市場未來發展預測

第12章 美國的經皮吸收貼片臨床實驗平台分析:各企業,各適應症,各Phase

  • 研究階段
  • 前臨床階段
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 申請完畢
  • 已通過核准

第13章 已上市的經皮吸收貼片臨床分析:各企業,各適應症

第14章 開發中斷/中止的經皮吸收貼片臨床分析:各企業,各適應症,各Phase

  • 沒有開發報告
  • 中斷
  • 市場撤退
  • 中止

第15章 競爭情形

  • 3M Pharmaceuticals
  • Acrux
  • Agile Therapeutics
  • Allergan
  • ANI Pharmaceuticals
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Corium International
  • Chase Pharmaceuticals
  • DURECT Corporation
  • Endo Pharmaceuticals
  • Fempharm
  • 久光製藥
  • Immune Pharmaceuticals
  • Imprimis Pharmaceuticals
  • Ipsen Bioscience
  • Johnson & Johnson
  • LaSalle Laboratories
  • Lavipharm-increase
  • MINRAD International
  • NeurogesX
  • Noven Pharmaceuticals
  • NuPathe
  • Nuvo Research
  • Novartis
  • Pain Therapeutics
  • ProStrakan
  • Purdue Pharma
  • Sanofi
  • Scilex Pharmaceuticals
  • 千壽製藥
  • Somerset Pharmaceuticals
  • 帝國製藥
  • Therapeutic Discovery Corporation
  • Transdermal Delivery Solutions
  • UCB
  • Xel Pharmaceuticals
  • Zosano Pharma
目錄

Innovations in pharmaceutical industry have a long track record of showing commercialization potential with respect to emerging and feasible technology. In US, such innovations have high level of acceptance among various stake holders of the pharmaceutical industry. Transdermal patches have emerged as one such innovations which have rich history but main development has been observed in past decade. They have been improved from a mere piece of tape dipped in formulation to complex matrix system containing therapeutics offering higher control over drug delivery. Long-term usage, high cost-effectiveness, high compliance rates and easy availability are some of the major factors behind the growth of transdermal patches in US.

Consumer base for transdermal patches is quite high in US in comparison to other markets across the globe. Segments like female contraceptives and Nicotine Replacement Therapy (NRT) have received lots of attention in past years. Indications like Parkinson's disease and Alzheimer's disease have few transdermal patches and have unexplored opportunities in US market. While Insulin and vaccine patches are at different stages of clinical trials which would be introduced in coming years. Unexplored disease segments have less competition and lack of transdermal patches makes them suitable choice for potential transdermal patch developers. This scenario suggests that US transdermal patch market has lots of commercialization opportunities that have to be reaped in coming years.

Some of the transdermal patches have completed their product life cycle and have given way to generic transdermal patches. Several small/mid-sized transdermal patch developers can take benefit of this scenario. Side-by-side, transdermal manufacturers have developed capabilities to customize products according to client's necessities. Improvement of transdermal patch technology is also expected to place as material science and associated fields are also developing. These observations suggest that US transdermal patch market will offer several commercialization opportunities. In this way, US transdermal patch segment shows progress at every level reflecting that this segment is expected to grow several folds in coming years.

“US Transdermal Patch Market & Clinical Trial Insight” Report Highlights:

  • US Transdermal Patch Market Overview
  • Generic & Branded Transdermal Patches
  • US Transdermal Patch Market: Value Chain Analysis
  • US Transdermal Patch Contract Manufacturing Organization
  • US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
  • US Transdermal Patch Clinical Pipeline: 55 Patches
  • Majority Patches in Preclinical Phase: 27 Patches
  • Marketed Transdermal Patch Clinical Insight by Company & Indication
  • Marketed Transdermal Patches in US: 33 Patches

Table of Contents

1. Introduction to Transdermal Patch

2. Types of Transdermal Patches

  • 2.1. Single/ Multiple-Layer Drug-in-Adhesive
  • 2.2. Reservoir Transdermal Patches
  • 2.3. Matrix Based Transdermal Patches
  • 2.4. Vapor Patch
  • 2.5. Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

4. Advantages of Transdermal Patch

5. US Transdermal Patch Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Transdermal Patch Clinical Pipeline Overview

6. Generic & Branded Transdermal Patches

7. US Transdermal Patch Market: Value Chain Analysis

  • 7.1. Research & Development
  • 7.2. Manufacturing
  • 7.3. Marketing & Distribution
  • 7.4. Price to End User

8. US Transdermal Patch Contract Manufacturing Organization (CMO)

9. US Transdermal Patch Market Growth Frontiers

  • 9.1. Parkinson's Disease Transdermal Patch
  • 9.2. Alzheimer's Disease Transdermal Patch
  • 9.3. Female Contraceptive Transdermal Patch
  • 9.4. Nicotine Replacement Therapy Transdermal Patch
  • 9.5. Insulin Transdermal Patch
  • 9.6. Vaccine Transdermal Patch

10. US Transdermal Patch Market Landscape

  • 10.1. Favorable Market Parameters
  • 10.2. Commercialization Challenges

11. US Transdermal Patch Market Future Prospects

12. US Transdermal Patch Clinical Pipeline Insight by Company,Indication & Phase

  • 12.1. Research
  • 12.2. Preclinical
  • 12.3. Phase-I
  • 12.4. Phase-I/II
  • 12.5. Phase-II
  • 12.6. Phase-III
  • 12.7. Preregistration
  • 12.8. Registered

13. Marketed Transdermal Patch Clinical Insight by Company & Indication

14. Discontinued & Suspended Transdermal Patch Clinical Insight by Company, Indication & Phase

  • 14.1. No Development Reported
  • 14.2. Discontinued
  • 14.3. Market Withdrawal
  • 14.4. Suspended

15. Competitive Landscape

  • 15.1. 3M Pharmaceuticals
  • 15.2. Acrux
  • 15.3. Agile Therapeutics
  • 15.4. Allergan
  • 15.5. ANI Pharmaceuticals
  • 15.6. Antares Pharma
  • 15.7. Bayer HealthCare Pharmaceuticals
  • 15.8. Corium International
  • 15.9. Chase Pharmaceuticals
  • 15.10. DURECT Corporation
  • 15.11. Endo Pharmaceuticals
  • 15.12. Fempharm
  • 15.13. Hisamitsu Pharmaceutical
  • 15.14. Immune Pharmaceuticals
  • 15.15. Imprimis Pharmaceuticals
  • 15.16. Ipsen Bioscience
  • 15.17. Johnson & Johnson
  • 15.18. LaSalle Laboratories
  • 15.19. Lavipharm-increase
  • 15.20. MINRAD International
  • 15.21. NeurogesX
  • 15.22. Noven Pharmaceuticals
  • 15.23. NuPathe
  • 15.24. Nuvo Research
  • 15.25. Novartis
  • 15.26. Pain Therapeutics
  • 15.27. ProStrakan
  • 15.28. Purdue Pharma
  • 15.29. Sanofi
  • 15.30. Scilex Pharmaceuticals
  • 15.31. Senju Pharmaceutical
  • 15.32. Somerset Pharmaceuticals
  • 15.33. Teikoku Seiyaku
  • 15.34. Therapeutic Discovery Corporation
  • 15.35. Transdermal Delivery Solutions
  • 15.36. UCB
  • 15.37. Xel Pharmaceuticals
  • 15.38. Zosano Pharma
Back to Top